Comparison of three doses of amikacin on alternate days with a daily dose of meropenem during the same period for the treatment of urinary tract infection with E. coli: a double-blind clinical trial

Table 1 Frequency of the measured variables before the treatment

Variable	Groups	Value	P-value
Age	Amikacin	20.5 ± 46.6	0.89✝
Age	Meropenem	13.6 ± 46.6	0.89✝
Female	Amikacin	21 (75%)	0.51
Female	Meropenem	27 (81.7%)	0.51
History of UTI	Amikacin	14 (50%)	0.55
History of UTI	Meropenem	19 (57.6%)	0.55
Dysuria	Amikacin	25 (89.3%)	1 *
Dysuria	Meropenem	29 (87.9%)	1 *
Frequent urination	Amikacin	25 (89.3%)	1 *
Frequent urination	Meropenem	29 (87.9%)	1 *
Abdominal pain	Amikacin	6 (21.4%)	0.08
Abdominal pain	Meropenem	14 (42.4%)	0.08
Flank pain	Amikacin	12 (42.9%)	0.06
Flank pain	Meropenem	22 (66.7%)	0.06
Suprapubic pain	Amikacin	19 (67.9%)	0.4
Suprapubic pain	Meropenem	19 (57.6%)	0.4
Costovertebral angle tenderness (CVAT)	Amikacin	13 (46.4%)	0.11
Costovertebral angle tenderness (CVAT)	Meropenem	22 (66.7%)	0.11

ISSN: 1756-0500